{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:13:52Z","timestamp":1793042032655,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60369-1","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:12:17Z","timestamp":1748466737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Tissue-agnostic cancer therapies: promise, reality, and the path forward"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"60369_CR1","first-page":"433","volume":"74","author":"V Subbiah","year":"2024","unstructured":"Subbiah, V., Gouda, M. A., Ryll, B., Burris, H. A. III & Kurzrock, R. The evolving landscape of tissue-agnostic therapies in precision oncology. CA: A Cancer J. Clinicians 74, 433\u2013452 (2024).","journal-title":"CA: A Cancer J. Clinicians"},{"key":"60369_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.ccell.2024.08.010","volume":"42","author":"V Subbiah","year":"2024","unstructured":"Subbiah, V. & Kurzrock, R. Precision oncology across the ages: impact on children, adolescents, and young adults. Cancer Cell 42, 1473\u20131479 (2024).","journal-title":"Cancer Cell"},{"key":"60369_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57941-0","volume":"16","author":"GW Sledge","year":"2025","unstructured":"Sledge, G. W. et al. Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. Nat. Commun. 16, 2646 (2025).","journal-title":"Nat. Commun."},{"key":"60369_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","volume":"166","author":"NJ Robert","year":"2022","unstructured":"Robert, N. J. et al. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US oncology network. Lung Cancer 166, 197\u2013204 (2022).","journal-title":"Lung Cancer"},{"key":"60369_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/d41586-024-00216-3","volume":"626","author":"F Andr\u00e9","year":"2024","unstructured":"Andr\u00e9, F., Rassy, E., Marabelle, A., Michiels, S. & Besse, B. Forget lung, breast or prostate cancer: why tumour naming needs to change. Nature 626, 26\u201329 (2024).","journal-title":"Nature"},{"key":"60369_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.trecan.2017.12.004","volume":"4","author":"V Subbiah","year":"2018","unstructured":"Subbiah, V. & Kurzrock, R. Challenging standard-of-care paradigms in the precision oncology era. Trends Cancer 4, 101\u2013109 (2018).","journal-title":"Trends Cancer"},{"key":"60369_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2159-8290.CD-19-1265","volume":"10","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V. et al. Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers. Cancer Discov. 10, 657\u2013663 (2020).","journal-title":"Cancer Discov."},{"key":"60369_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat. Med 29, 1103\u20131112 (2023).","journal-title":"Nat. Med"},{"key":"60369_CR9","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.esmoop.2023.100788","volume":"8","author":"MA Gouda","year":"2023","unstructured":"Gouda, M. A. & Subbiah, V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open 8, 100788 (2023).","journal-title":"ESMO Open"},{"key":"60369_CR10","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"60369_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","volume":"35","author":"CB Westphalen","year":"2024","unstructured":"Westphalen, C. B. et al. The ESMO tumour-agnostic classifier and screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ann. Oncol. 35, 936\u2013953 (2024).","journal-title":"Ann. Oncol."},{"key":"60369_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","volume":"31","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V., Solit, D. B., Chan, T. A. & Kurzrock, R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >\/=10: a decision centered on empowering patients and their physicians. Ann. Oncol. 31, 1115\u20131118 (2020).","journal-title":"Ann. Oncol."},{"key":"60369_CR13","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.22.02833","volume":"41","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. & Kurzrock, R. Universal germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis. J. Clin. Oncol. 41, 3100\u20133103 (2023).","journal-title":"J. Clin. Oncol."},{"key":"60369_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1158\/2159-8290.CD-24-0017","volume":"14","author":"V Subbiah","year":"2024","unstructured":"Subbiah, V., Horgan, D. & Subbiah, I. M. A vision for democratizing next-generation oncology clinical trials. Cancer Discov. 14, 579\u2013584 (2024).","journal-title":"Cancer Discov."},{"key":"60369_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. The next generation of evidence-based medicine. Nat. Med. 29, 49\u201358 (2023).","journal-title":"Nat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60369-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60369-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60369-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:12:17Z","timestamp":1748466737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60369-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60369"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60369-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The content is solely the responsibility of the author and does not necessarily represent the official views of the institution. Vivek Subbiah reports: Research funding for clinical trials paid to institution from Abbvie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicine, Boston Biomedical, Boston Pharmaceuticals, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmith-Kline, Idera Pharmaceuticals, Incyte, Inhibrix, Eli Lilly\/Loxo Oncology, MedImmune, NanoCarrier, Novartis, PharmaMar, Pfizer, Relay Therapeutics,Roche\/Genentech, Takeda, Turning Point Therapeutics, and Vegenics. Consulting\/advisory role (paid to institution) from Abbvie, Astex Pharmaceuticals, AstraZeneca, Bayer, Genmab, Incyte, Lilly\/Loxo Oncology, Novartis, Obsidian Therapeutics, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, Roche, Endeavor Biomedicines, RevMed, LabGenius therapeutics, Other consulting\/advisory role\/CME from Helsinn Healthcare, Jazz Pharmaceuticals, Incyte, Loxo Oncology \/Lilly, Novartis, Relay Therapeutics, Daiichi Sankyo, Illumina, Bayer, Medscape, OncLive, Clinical Care Communications, PERS, and Med learning group.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interest statement"}}],"article-number":"4972"}}